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AJH 2007; 20:1007–1015Low dietary intake of calcium stimulates the activation of
vitamin D3 precursors to calcitriol in the kidney. This
circulating hormone raises blood and urinary calcium by
increasing both gastrointestinal absorption of calcium and
bone resorption. Renal activation of vitamin D3 is under
tight feedback control. Macrophages also activate vitamin
D3, but, unlike renal tubular cells, they lack feedback
suppression of the activating 1-hydroxylase. In large-
scale epidemiologic studies, blood pressure correlated pos-
itively with serum and urinary calcium but inversely with
the dietary intake of calcium. Several population-based
reports, including the Framingham Study, noticed an as-
sociation of carotid plaques, arterial calcification, and in-
creased arterial stiffness with lower bone-mineral content.
Randomized clinical trials of calcium supplementation did
not demonstrate a consistent effect on blood pressure.
Macrophages in atherosclerotic lesions can locally activate
vitamin D3 to calcitriol, which might contribute to arterial
stiffening and hypertension. Calcitriol acts as a vasoactive
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Published by Elsevier Inc.and pro-oxidative substance on vascular smooth muscle
cells. In animal models, active vitamin D3 promotes arte-
rial stiffening and the pathogenesis of systolic hyperten-
sion and perpetuates a self-sustaining cycle leading to
arterial damage and calcification. On the other hand, active
vitamin D3 inhibits renin activity, thereby decreasing
blood pressure in short-term, randomized trials. This arti-
cle assesses the potential role of active vitamin D3 in
causing cardiovascular complications via its effects on the
structure of the arterial wall and the pathogenesis of hy-
pertension. To set the stage and open up new perspectives,
our article also summarizes the pathways leading to the
renal and extrarenal activation and metabolism of vitamin
D3 and will propose some directions for further research in
this complex field. Am J Hypertens 2007;20:1007–1015
© 2007 American Journal of Hypertension, Ltd.
Key Words: Vitamin D, macrophages, chronic inflam-
matory disease, arterial stiffening, atherosclerosis, hyper-
tension.T he roles of calcium and vitamin D3 in blood-pres-sure regulation have been widely reviewed,1–5 andtheir effects were assessed in a large number of
clinical trials and epidemiologic studies. Epidemiologic
surveys in industrialized countries and developing societ-
ies revealed an inverse association between blood pressure
and the dietary intake of dairy products or calcium.6,7
Several large-scale studies showed a positive relationship
between blood pressure and either serum total calcium or
24-h calcium excretion. Quantitative overviews of ran-
domized clinical trials of calcium supplementation did
not document a consistent effect on blood pressure. Sim-
ilarly discordant results were reported on the effects of
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bone turnover. Accumulating epidemiologic evidence in-
dicates that osteoporosis, obesity, and cardiovascular dis-
eases frequently coexist, suggesting a link between bone,
adipose, and vascular tissues.9 Higher calcium intake,
often specifically from dairy products, in conjunction with
normalization of vitamin D3 status through adequate solar
exposure, was conclusively shown to augment bone gain
during growth and to slow age-related bone loss and
fracture rate.10 Decreased bone-mineral content is asso-
ciated with increased arterial stiffness, as assessed by
pulse-wave velocity measurements.11 Although numerous
population-based studies, including the Framingham sur-
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calcification,13 hypertension,14 and increased arterial stiff-
ness11 with lower bone-mineral content, clinical trials and
epidemiologic studies on the role of vitamin D3 in the
pathogenesis of hypertension and arterial disease yielded
inconclusive or contradictory results.15–17
The infiltration and accumulation of macrophages in
atherosclerotic lesions,18 and their ability to locally acti-
vate circulating precursors of vitamin D3, might cause
deleterious effects on the structure and function of the
arterial media by facilitating calcification, leading to arte-
rial stiffening. The administration of pharmacologic doses
of vitamin D3 to rats and rabbits generates reproducible
animal models of arterial stiffening and isolated systolic
hypertension.19 Moreover, the progressive shift from the
renal to extrarenal activation of vitamin D3 in chronic
inflammatory conditions bypasses the tight renal feedback
systems for calcium homeostasis. These long-term proc-
esses are confounded by the inhibiting effect of active
vitamin D3 on renin activity, which causes a mild blood-
pressure-lowering effect.20
In this article, we assess the potential role of active
vitamin D3 in the causation of cardiovascular complica-
tions via its effects on the structure of the arterial wall and
the pathogenesis of hypertension. To set the stage for our
article, we summarize the pathways leading to the renal
and extrarenal activation and metabolism of vitamin D3.
Based on the reviewed evidence, we propose some direc-
tions for further research in this complex field.
Renal and Extrarenal Activation
and Metabolism of Vitamin D3
Precursors of vitamin D3 are generated in the skin from
7-deoxycholesterol by exposure to ultraviolet light in the
B-spectrum (UVB). Human food from animal sources and
dietary supplements also contain vitamin D3 precursors
(cholecalciferol).21,22 Exposure to sunlight will generate
approximately 200 IU of cholecalciferol after 10 min of
whole-body irradiation. Endogenously synthesized precur-
sors are UVB-unstable and thus inactivated before enter-
ing the circulation, preventing an “endogenous overdose”
during prolonged solar exposure.22 Cholecalciferol from
animal food sources and supplements readily reaches the
circulation after intestinal absorption.21
The activation of circulating cholecalciferol to the ac-
tive hormone is biphasic (Figs. 1 and 2). First, hepatic
25-hydroxylase activity converts circulating precursors to
calcidiol (25-[OH]-D3). The principal site of the second
hydroxylation, as a result of 1-hydroxylase activity in the
proximal tubules of the kidney, is central to the endocrine
function of vitamin D3 as a parathyroid hormone-stimu-
lated modulator of calcium homeostasis.23 Renal tubular
cells express both 24-hydroxylase and 1,-hydroxylase
(Fig. 2). Strict transcriptional feedback mechanisms bal-
ance the production of 24,25-(OH)2-D3 and calcitriol
(1,25-[OH]2-D3), the active hormone.21 All target cells forvitamin D3 express 24-hydroxylase, to inactivate calcitriol
to calcitroic acid.21
Senescence of the skin, defined as changes in pigmen-
tation and thickness, underlies an age-related decrease in
endogenous synthesis of vitamin D3 precursors. Combined
with a lifestyle with less solar exposure, it is the main
cause of hypovitaminosis D3 in the elderly, ultimately
leading to osteoporosis.24,25 On the other hand, the capac-
ity to absorb oral precursors of vitamin D3 does not decline
with age. The administration of vitamin D3 supplements
results in elevated circulating levels of 25-OH-D3 in both
young and older adults.25
The intestinal absorption of orally ingested cholecalcif-
erol is not controlled by feedback. Because of the lack of
tight feedback on liver 25-hydroxylase, high oral doses of
FIG. 1. Structure of vitamin D precursors and metabolites.cholecalciferol induce elevated levels of circulating 25-
1009AJH–September 2007–VOL. 20, NO. 9 ARTERIES AND VITAMIN Dhydroxyvitamin-D3 that can persist for months, thereby
maintaining hypercalcemia. In extreme cases, metastatic
calcification of the liver and lungs occurs.26 The adminis-
tration of pharmacological doses of vitamin D3 to rats and
rabbits generates reproducible animal models of isolated
systolic hypertension.19 The underlying mechanism rests
upon the upregulation of vitamin D3 receptors in vascular
smooth muscle cells (VSMCs), causing an increased cal-
cium influx, which ultimately leads to disruption of the
elastin fibers and calcium deposition in the medial layer of
large arteries.27 Bisphosphanates28,29 and calcium channel
blockers, such as amlodipine, antagonize and can even
reverse these arterial calcifications.30,31
Apart from strictly controlled vitamin D3 activation in
the renal proximal tubules, several other cell types can
express 1,-hydroxylase, enabling extrarenal activation of
circulating 25-OH-D3 to the active hormonal form.21,32
These include dermal and intestinal epithelial cells, mono-
cytic cell lines, and macrophages.33 Studies that described
the presence and action of vitamin D3 in primitive organ-
FIG. 2. Pathways in the activation of vitamin D.isms such as phytoplanktons prompted speculation as tothe function of vitamin D3 in these organisms that lack
bone tissue.34,35
Extrarenally, in areas of inflammation, macrophages
express 1,-hydroxylase but lack the tight feedback mech-
anisms present in renal tubular cells (Fig. 2). Only in case
of excessive local production does 1,25-(OH)2-vitamin-D3
spill over into the general circulation.26 In the 1980s,
studies of nonclassical effects of 1,25-(OH)2-D3 reported
that patients with granulomatous diseases, such as sarcoid-
osis, had elevated circulating levels of 1,25-(OH)2-D3.36
This was due to the extrarenal synthesis of 1,25-(OH)2-D3
by activated macrophages.37–39 Subsequently, nearly 20
other forms of granulomatous diseases, such as Crohn’s
disease, were reported to be associated with increased
levels of 1,25-(OH)2-D3. In these cases, inflammatory
activity more closely correlated with the serum concentra-
tion of 25-OH-D3 than with that of 1,25-(OH)2-D3. Gran-
ulomatous inflammatory processes elevate calcitriol levels
and sometimes result in hypercalcemia.40,41 Moreover,
decreased bone-mineral content is a common finding in
these states of chronic inflammation.42–44
1010 AJH–September 2007–VOL. 20, NO. 9ARTERIES AND VITAMIN DEffects of Active
Vitamin D3 on the Arterial Wall
The normal arterial media is a well-organized structure
consisting of vascular smooth muscle cells and extracel-
lular matrix proteins. The VSMCs produce elastin and
collagens.45 They also regulate the active component of
vascular tone by varying the diameter of the arterial lumen
under the control of circulating hormones, paracrine sub-
stances, and neurotransmitters.30 Elastin fibers maintain a
continuous blood flow by absorbing energy during systole
and recoiling during diastole. They also fulfill a structural
role by containing VSMCs in concentric layers.45 The
integrity of the ring structure of the arterial wall depends
on the interaction between fibrillin-1, a protein associated
with elastin, and V3 integrins expressed on the outer
FIG. 3. Expressible vitamin D-metabolizing enzymes and presence
of vitamin D receptor (VDR) by cell type. Solid portions of bars
show level of 1,25-(OH)2-D production possible per cell type. Open
bar symbolizes lowest possible level.FIG. 4. Local and systemic effects of vitamin D.side of the VSMC membrane.45 Nonelastic collagen rein-
forces the arterial wall, limiting distension at elevated
blood pressures. In the wall of atherosclerotic arteries,
elastin fibers become fragmented and displaced. Loss of
contact between VSMCs and elastin and between V3
integrins and fibrillin-1, respectively, leads to dedifferen-
tiation and the migration of VSMCs.45,46
In atherosclerotic lesions, macrophages infiltrate the
arterial wall.18 Their ability to activate circulating precur-
sors to calcitriol can cause deleterious effects on the struc-
ture and function of the arterial media. Antigen-presenting
cells can act as an abundant source of 1,25-(OH)2-D3,
depending on the degree of disease activity. Coupled with
the lack of 24-hydroxylase feedback regulation, this re-
sults in the unregulated production of active vitamin D333
(Figs. 2 and 3).
In vitro studies of VSMCs revealed three pathways via
which 1,25-dihydroxyvitamin D3 might contribute to the
pathogenesis of arterial lesions: stimulation of calcium
influx,47 interference with the basic cellular housekeeping
machinery,48 and activation of protein kinase–mediated
pathways49,50 (Fig. 4, left). First, 1,25-dihydroxyvitamin
D3 activates L-type calcium channels.47 The resultant in-
ward flow of calcium ions leads to an enhanced contractile
response to vasopressors, such as norepinephrine, and
promotes calcium deposition on elastin fibers.30 Second,
1011AJH–September 2007–VOL. 20, NO. 9 ARTERIES AND VITAMIN Dby inhibiting the transcription of parathyroid hormone-
related peptide and stimulating the expression of osteopontin,
1,25-dihydroxyvitamin D3 promotes calcification.48 Third,
1,25-dihydroxyvitamin D3 dose-dependently activates p38
mitogen-activated protein kinase49 and phosphatidyl-ino-
sitol kinase.50 Once activated, these signal transducers, in
concert with cytokines and growth factors, including an-
giotensin II, induce cell dedifferentiation, promote cell
migration, and increase oxidative stress, thereby leading to
the structural disintegration and stiffening of the arterial
wall.49
Some cross-sectional studies reported an inverse asso-
ciation between coronary artery calcification and the cir-
culating levels of 1,25-dihydroxyvitamin D3,16,17 whereas
others failed to demonstrate such an association.15
Hypertension and Vitamin D3
The effects of locally activated vitamin D3 on the arterial
wall contradict the acute blood-pressure-lowering effect of
oral vitamin D3 precursor administration as seen in clinical
trials. For example, in a randomized clinical trial, supple-
mentation of elderly women with vitamin D3 precursors
for 8 weeks resulted in a significant decrease of systolic
blood pressure by 9.3%,20 perhaps because of the inhibi-
tory effect of both 1,25-dihydroxyvitamin-D351,52 and cal-
cium53 on renin secretion and activity. Cross-sectional
surveys noted an inverse association of active vitamin D3
concentrations and blood pressure.54 Recent findings on
the modulation of the renin-angiotensin system by calcium
and vitamin D3 set some of the above clinical observations
in a more logical perspective (Fig. 4, right).
As reviewed elsewhere,5,55,56 several large-scale stud-
ies showed a positive relationship between blood pressure
and either serum total calcium or 24-h urinary calcium
excretion. Acute hypocalcemia produced orthostatic hypo-
tension in human volunteers, whereas an acute elevation of
serum calcium induced a parallel rise in peripheral vascu-
lar resistance and blood pressure. Recently, Klar et al
described the downregulation of renin expression in jux-
taglomerular cells by calcium. An increase of cytosolic
calcium inhibits renin gene transcription and destabilizes
renin mRNA.53
Resnick and Laragh57 and Resnick et al58 described
differences in the serum concentrations of calcium, para-
thyroid hormone, and active vitamin D3 levels between
low-renin and high-renin hypertensive patients. Short-term
administration of the hormonally active form (calcitriol)
resulted in a pressor response in low-renin hypertension
and a decrease in blood pressure in subjects with high
renin levels. However, active vitamin D3 given over a
period of 6 months yielded a decline in blood pressure in
low-renin hypertensive patients.57–59 Calcitriol adminis-
tration in high-renin hypertensives in a clinical trial by
Burgess et al produced similar findings, leading to the
hypothesis that 1,25-dihydroxyvitamin D3 might be a me-diator of the response of high-renin hypertensive patients
to high sodium intake.60
Twenty years later, Li et al51 described increased renin
transcription in vitamin D receptor-null mice. Inhibition of
1,25-dihydroxyvitamin D3 synthesis in wild-type mice in-
creased the expression of renin, whereas the injection of
active vitamin D3 down-regulated renin transcription.
Some vitamin D3 analogs inhibit renin gene transcription
without a pronounced calcamic effect and were proposed
as novel antihypertensive compounds.52
Perspectives for Further Research
In cases of local activation of vitamin D3 by macrophages,
spillover to the circulation only occurs during massive
overproduction.33 Interpersonal variations in skin pigmen-
tation, geographic latitude, habitual and seasonal sun ex-
posure, dietary habits, and the use of anti-inflammatory
and lipid-lowering medications all have an influence on
vitamin D3 levels.61 These factors would most likely con-
found the long-term associations between cardiovascu-
lar disease and serum levels of vitamin D3 and probably
explain the null findings of some recent longitudinal
studies.7,8
Animal experiments, over and beyond those already
published,19,27,28 are unlikely to generate more relevant
results. Indeed, in short-lived rodents, pharmacologic
doses of vitamin D3 are required to mimic age-related
arterial structural damage and calcification, which in hu-
mans occur over many years, and usually decades.19,30 It is
also impossible to measure in vivo the local concentration
of 1,25-dihydroxyvitamin D3 in the arterial wall. In ar-
thritic patients, macrophages in synovial fluid locally pro-
duce biologically relevant concentrations of active vitamin
D3. In contrast to atherosclerotic lesions, 1,-hydroxylase
activity can easily be assessed in aspirated synovial fluid.62
Preparations with vitamin D3 precursors are widely
available as over-the-counter drugs, whereas active vitamin
D3 preparations (eg, alphacalcidol) are strictly regulated
substances. They do not require activation by 1,-hydrox-
ylase, whether renally or extrarenally expressed, to exert
their genomic and nongenomic effects. In randomized
placebo-controlled studies by Lind et al, the administration
of alphacalcidol (active vitamin D3) did not influence the
serum levels of both 25-OH-D3 and 1,25-(OH)2-D3, and
decreased blood pressure in healthy individuals but also
induced a 50% increase in urinary calcium excretion,
which is associated with hypertension in some population
studies.63 Administration of active vitamin D3 in middle-
aged, vitamin D3–replete individuals with impaired glu-
cose tolerance did not produce significant effects on blood
pressure, insulin sensitivity, or glucose tolerance, leading
to the conclusion that these patients do not benefit from
supplementation.64 The same authors also demonstrated
that the reduction of blood pressure during long-term
treatment with active vitamin D3 is dependent on plasma
renin activity and calcium status in patients with essential
b
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1012 AJH–September 2007–VOL. 20, NO. 9ARTERIES AND VITAMIN Dhypertension.65 The results from the latter study supported
the idea of a relationship between calcium metabolism
and the renin-aldosterone system in essential hyperten-
sion, and suggested a beneficial effect of vitamin D3
supplementation on blood pressure in patients with low-
renin hypertension.65 Previous studies, which involved the
administration of active vitamin D3, did not provide infor-
mation on the extrarenal activation of vitamin D3 precur-
sors as proposed in the current article.
A possible approach to assess the level of extrarenal
activation of circulating precursors of vitamin D3 to the
active hormonal form would necessitate the measurement
of calcitroic acid, the metabolite of vitamin D3, in urine
collections, and the assessment of 24-h urinary excretion in
comparison with circulating concentrations of 25-OH-D3,
1,25-(OH)2-D3, markers of inflammation, and white blood
cell counts. Low circulating concentrations of active vita-
min D3, combined with increased urinary excretion of
calcitroic acid, suggest the extrarenal activation of vitamin
D3. Indeed, except for extreme cases of granulomatous
infections, extrarenally activated vitamin D3 is locally
metabolized before spilling over into the circulation in its
active form.26 Although the in vitro evidence on the local
effects of active vitamin D3 on the arterial wall is convinc-
ing, longitudinal research into high-fidelity arterial pheno-
types and the possible associations with vitamin D3
metabolism in various states of inflammation might shed
new light on the cardiovascular impact of supplementation
and solar exposure.
We propose to take advantage of the natural genetic
randomization during sexual reproduction66 by studying
the possible associations of blood pressure and arterial
phenotypes67 with functionally active polymorphisms in
the enzymes involved in the generation or catabolism of
25-hydroxyvitamin D3 or 1,25-dihydroxyvitamin D3, or
in signal transduction via the vitamin D3 receptor.68 Al-
leles controlling the innate activity of vitamin D3 are
randomly transmitted from parents to offspring, so that
confounding factors are evenly distributed in subjects who
are or are not exposed to higher vitamin D3 activity.
Moreover, this genetic approach would also overcome the
problem of reverse causality, because the genotype is
determined before the onset of disease. Remarkably, as
shown in Table 1, some of the candidate genes involved in
the synthetic or catabolic pathways of vitamin D3 or in
mediating its activity are located in chromosomal regions
previously linked to systolic or diastolic blood pres-
sure,69–71 mean arterial pressure,72 pulse pressure,69 or
hypertension.73,74 Muray et al demonstrated a positive
association of blood pressure and circulating levels of
25-OH-vitamin D3 in men with the BB-Bsm I vitamin
D-receptor genotype.75 Along the lines of this article,
several researchers reported associations of myocardial
infarction,76 coronary heart disease,77 and aortic valve
stenosis78 with genetic variation in the vitamin D3 re-
ceptor. Ta CY CY CY SC DH Vit CY SU CY LS
S
A
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2
5
-
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Since the introduction of vitamin D3 supplements in the
1930s to prevent rickets, numerous reports described the
symptoms of iatrogenic or accidental overdosage with
vitamin D3.26,79,80 The most common symptoms are hy-
percalcemia; calcinosis around joints; and metastatic cal-
cifications in the arteries, lungs, liver, spleen, and kidneys.
Currently, there is no consensus about the recommended
daily allowance of vitamin D3.81 In several countries, milk
and food supplements are fortified with vitamin D3 on an
industrial scale to reduce the risk for hypovitaminosis
D3.26 Maintenance of current sun-avoidance policies to
prevent skin cancer while supplementing food with vita-
min D3 might not be the optimal way to balance the risks
of inadequate exposure to UVB.61
Cardiovascular disease is the leading cause of morbid-
ity and mortality in developed and most developing na-
tions. The seemingly beneficial effects on blood pressure
seen during short-term supplementation with vitamin D3
have never been confirmed for its prolonged use. Given
the currently reviewed extraskeletal effects of vitamin D3
and the interaction with inflammatory disease, this “old”
topic should be readdressed. Although the beneficial effect
of a lifelong calcium-replete status on both bone and
cardiovascular health is quite clear, the optimal dose of
vitamin D3 and how to acquire it, are still under discus-
sion. If further evidence confirmed that excessive exposure
to oral vitamin D3 is a risk factor for arterial disease, these
findings should instigate a reassessment of the guidelines
for the recommended daily allowance, food fortification,
use of vitamin D3 supplementation, and exposure to ultra-
violet radiation, in clinical practice.
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